Department of Pediatrics, Radboud University Medical Center, Nijmegen, the Netherlands.
Laboratory for Immunology, Department of Pediatrics, Leiden University Medical Center, Leiden, the Netherlands.
Pediatr Neurol. 2020 Dec;113:26-32. doi: 10.1016/j.pediatrneurol.2020.07.014. Epub 2020 Jul 28.
We aimed to expand the number of currently known pathogenic PNKP mutations, to study the phenotypic spectrum, including radiological characteristics and genotype-phenotype correlations, and to assess whether immunodeficiency and increased cancer risk are part of the DNA repair disorder caused by mutations in the PNKP gene.
We evaluated nine patients with PNKP mutations. A neurological history and examination was obtained. All patients had undergone neuroimaging and genetic testing as part of the prior diagnostic process. Laboratory measurements included potential biomarkers, and, in the context of a DNA repair disorder, we performed a detailed immunologic evaluation, including B cell repertoire analysis.
We identified three new mutations in the PNKP gene and confirm the phenotypic spectrum of PNKP-associated disease, ranging from microcephaly, seizures, and developmental delay to ataxia with oculomotor apraxia type 4. Irrespective of the phenotype, alpha-fetoprotein is a biochemical marker and increases with age and progression of the disease. On neuroimaging, (progressive) cerebellar atrophy was a universal feature. No clinical signs of immunodeficiency were present, and immunologic assessment was unremarkable. One patient developed cancer, but this was attributed to a concurrent von Hippel-Lindau mutation.
Immunodeficiency and cancer predisposition do not appear to be part of PNKP-associated disease, contrasting many other DNA repair disorders. Furthermore, our study illustrates that the previously described syndromes microcephaly, seizures, and developmental delay, and ataxia with oculomotor apraxia type 4, represent the extremes of an overlapping spectrum of disease. Cerebellar atrophy and elevated serum alpha-fetoprotein levels are early diagnostic findings across the entire phenotypical spectrum.
我们旨在增加目前已知的致病性 PNKP 突变数量,研究表型谱,包括放射学特征和基因型-表型相关性,并评估免疫缺陷和癌症风险增加是否是 PNKP 基因突变引起的 DNA 修复障碍的一部分。
我们评估了 9 名 PNKP 突变患者。我们获取了他们的神经病史和检查结果。所有患者均已接受神经影像学和基因检测,作为先前诊断过程的一部分。实验室测量包括潜在的生物标志物,并且,在 DNA 修复障碍的背景下,我们进行了详细的免疫评估,包括 B 细胞库分析。
我们在 PNKP 基因中发现了三个新突变,并证实了 PNKP 相关疾病的表型谱,范围从小头畸形、癫痫和发育迟缓到 4 型眼动运动性共济失调。无论表型如何,甲胎蛋白是一种生化标志物,并且随着年龄和疾病的进展而增加。在神经影像学上,(进行性)小脑萎缩是一个普遍特征。没有免疫缺陷的临床迹象,免疫评估也无异常。一名患者发生了癌症,但这归因于并发的 von Hippel-Lindau 突变。
免疫缺陷和癌症易感性似乎不是 PNKP 相关疾病的一部分,与许多其他 DNA 修复障碍形成对比。此外,我们的研究表明,以前描述的小头畸形、癫痫和发育迟缓以及 4 型眼动运动性共济失调综合征代表了重叠疾病谱的极端。小脑萎缩和血清甲胎蛋白水平升高是整个表型谱的早期诊断发现。